Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer - Wikidata - wikimedia - TriplyDB

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer

http://www.wikidata.org/entity/Q35898597

about

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data.Racial disparity in metabolic regulation of cancer.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status.Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.Racial diversity of actionable mutations in non-small cell lung cancer.Lung cancer mutations and use of targeted agents in Hispanics Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.A growing family: adding mutated Erbb4 as a novel cancer target Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.Cancer genes in lung cancer: racial disparities: are there any?Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research.Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma.Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.BIBW 2992 in non-small cell lung cancer.Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Targeted therapy of non-small-cell lung carcinoma.Genomic biomarkers for patient selection and stratification: the cancer paradigm.Molecular alterations in non-small-cell lung cancer: perspective for targeted therapy and specimen management for the bronchoscopist.Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival.Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations.Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians.Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.Simpson's paradox - aggregating and partitioning populations in health disparities of lung cancer patients.Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung.Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.Lung Cancer Health Disparities.Race and genomics in the Veterans Health Administration.EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants.

P2860

Q26828860-A90EADCB-094A-4824-9711-8D918302B50B Q30915526-A4F71A4F-BF77-40C9-B5C9-6AFFD0081D67 Q33906704-0EB91E2D-2EEE-4B0D-85ED-4EF2A23AEF90 Q34159011-588C9456-64E0-45C6-A2BD-414B01114656 Q34429176-F3CAADA3-5D39-464E-B91A-8EE56DC4C5ED Q34575903-A2CD8C35-C386-45C2-A480-B560F03D1B98 Q34673282-87BA0DA5-E0CF-42B3-B141-7F2C3E6C9054 Q35007995-8F468F23-07FF-4066-8C29-5E4E80CC0CCE Q35636924-F9B6B28D-594F-4F5A-8235-6DFEE1839467 Q35671373-6F1C8EC2-E40B-4242-8484-539CC9E72817 Q35915133-AD0FE8AA-8E62-447A-9E9E-EAB3C9C29664 Q35943089-9E28A8D1-5A62-41BB-AEA0-660947A05EB8 Q36062442-CB0CEB86-A53C-4A1E-8DA5-BA4A3E0F070E Q36200850-AAA17668-9A63-414B-98E0-03B13C556F56 Q36481954-254EFEB9-D63A-4AC4-B639-F4669D35A10A Q37110396-5BC7BADF-9587-43D4-B837-FE2C27911AE8 Q37238134-C92E183D-7124-40CA-AEA5-2D278A934C05 Q37288681-2B81340D-5DEE-4263-98F6-0758BF432361 Q37651033-A0C48A0D-8C9C-4D0F-9063-A0DB504E49A1 Q37684483-A5E1B5BF-ADE1-4067-AB3A-15302087FD90 Q37841599-95CBDCA7-FD05-4C18-BD4B-8A72345AB478 Q37863629-7DB37940-4504-4382-881D-BC1C18D81DA3 Q37897792-B66D34B1-77D6-4F8C-8CCC-941889B33394 Q38060203-8C4A0904-E64E-4A99-9BC0-8056BF3CC176 Q38258822-F343138E-C65A-4B55-9C8E-1DC79BA523B3 Q38471484-51E79262-8EB3-46C9-8C44-FC47BA6B8DB5 Q38661269-020D3E27-1343-44F4-87EE-C9E241B3AF70 Q38816190-0FA6BD6D-24DC-4CD9-AA9E-652C4668BF31 Q40368173-1AE58A72-FB7B-4EEE-89F5-67C069BDDDB0 Q41612456-4C427F47-C0FB-447C-AA34-D3F7E4010CEC Q44695743-F6451FEB-8782-4B8E-85CB-C516857004E5 Q46505499-D3F654F9-E797-438F-962C-6E9E34859B07 Q46607446-A1D36405-4415-43F8-8C1D-92F0300802D2 Q47566249-E60E4108-7514-45A2-9099-FDE2400DB51E Q48478420-BA7063D5-E906-4E95-8C2E-001A670D1194 Q53177073-B42380AD-61BB-41F9-A7E9-CFE9A0964715 Q53833517-9DC85037-C27B-4AF7-8EC9-5C2DFF40792F Q54515361-5EAE7EF8-9D0D-4944-B542-A0740BA605F1 Q54628554-8F471D80-87AD-4493-9BFD-0387D4C7232F Q55401345-2F469FFE-66BF-4784-905E-7EE0136902FE

P2860

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer

http://www.wikidata.org/entity/Q35898597

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@ast

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@en

type

label

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@ast

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@en

prefLabel

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@ast

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@en

P1433

Q35898597-3C4D2CBB-D96E-4EFD-8857-978ED5545948

P1476

Q35898597-10F1284A-7247-4FC4-A15D-ADBC9F35D06B

P2093

Q35898597-027DDE2F-3C82-436D-93D8-6076B26B5F81

Q35898597-2958B8AA-AD40-41B7-B599-6411B7078363

Q35898597-2BF30AF7-C5D5-4009-B0B4-FF8D6E96697F

Q35898597-351D72E9-D63C-42DE-994A-2729F2375101

Q35898597-4B6982A2-9502-4B72-98C5-BE1FB3B8ECA6

Q35898597-53CA6936-2EEF-43F1-ADD4-E80132F7255F

Q35898597-5EA4A06B-7FE1-4142-BA7E-A1AF9227992B

Q35898597-63D81C81-26EC-4312-A5FE-9B97CE4499FC

Q35898597-996CE407-E0D7-4A10-9C4B-8DAC0EB0DF47

Q35898597-A7A4E4B8-B648-474C-9A97-340E1BC1BC50

P2860

Q35898597-02D36F00-92D5-4471-9596-FEF529FE3C0C

Q35898597-03654F1E-EA16-4CD9-93FD-2AEF9E6A315B

Q35898597-0BA9AC0B-5C21-4D8F-BD54-19B8D65B914F

Q35898597-0E8CDEAA-7AEA-4C18-8CE6-101EDAEF5FC4

Q35898597-0F14C534-4DBE-4EC3-96BE-2289E1BD28B3

Q35898597-113C57B5-5C22-463D-A2C0-D17B62808821

Q35898597-15D8B3F8-9D3B-49F0-84D2-0BC04C9FC6F4

Q35898597-206665A8-01A7-48A6-ACAE-281C82EDD700

Q35898597-23459C95-20DF-4F3F-95C8-FA8F0B46A1A7

Q35898597-3D153B29-547A-43A1-AEA5-9D5B0D5B50E1

P304

Q35898597-53F1CF14-39D4-4AFB-9A9A-4BD929504DE8

P31

Q35898597-7BD6A28D-B2F7-4498-84D2-A561756695C7

P356

Q35898597-09D54399-6FED-4044-BFF1-C048B206CCC7

P407

Q35898597-52FA6793-B336-4A77-BEA7-64349E526D3E

P433

Q35898597-D69FF65F-CAC3-4220-AA52-8E9BB1EC739A

P478

Q35898597-417D19A9-9E79-4C70-9CD8-7FB83C40CF29

P577

Q35898597-801B7CB5-2D5F-4BBD-BDEA-70E88E594CC6

P698

Q35898597-520FD232-37FB-4911-A4F9-741A7CC23347

P932

Q35898597-EB2ABC2E-1D2A-4A74-9171-018A5F05C927

P356

JCO.2009.23.1431

P1433

Journal of Clinical Oncology

P1476

Genetic abnormalities of the E ...... ith non-small-cell lung cancer

@en

P2093

Ayad Hamdan

http://www.w3.org/2001/XMLSchema#string

Balazs Halmos

http://www.w3.org/2001/XMLSchema#string

Bradley Clifford

http://www.w3.org/2001/XMLSchema#string

Cheng Jin

http://www.w3.org/2001/XMLSchema#string

Federico Cappuzzo

http://www.w3.org/2001/XMLSchema#string

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Margaret Skokan

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Pingfu Fu

http://www.w3.org/2001/XMLSchema#string

Rom S Leidner

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Cancer statistics, 2008

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Erlotinib in previously treated non-small-cell lung cancer

P304

5620-5626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.23.1431

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19786660

http://www.w3.org/2001/XMLSchema#string

P932

3329938

http://www.w3.org/2001/XMLSchema#string